A Study of RO4917523 in Patients With Treatment Resistant Depression
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability and efficacy of RO4917523, in comparison to
placebo, in patients with treatment-resistant depression. Following a washout period from
existing anti-depressant medication, cohorts of patients will be randomized to receive daily
oral RO4917523 at up to five different doses (according to the safety and tolerability
observed at the lower doses during the study), or placebo. The anticipated time on study
treatment is 10 days (in an inpatient unit), and the target sample size is <100 individuals.